Volition webinar: Nu.Q NETs data insights

Volition webinar: Nu.Q NETs data insights

VolitionRx — 7 videos in collection

More on this equity

Volition (NYSE: VNRX) and Edison recently hosted a webinar in which Volition provided insights into the data it presented at ESICM 2024, highlighting research findings from three large independent studies (over 3,000 patients) on the potential use of Volition’s Nu.Q® NETs H3.1 assay to enhance sepsis management in clinical practice. The webinar explores the role of H3.1 nucleosomes in NETosis and why elevated levels of H3.1 are a cause for concern in sepsis patients, as well as examining how the Nu.Q NETs biomarker could predict organ failure. Volition also gave an update on its commercialisation efforts for Nu.Q NETs.


You may also be interested in these:

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free